Adlai Nortye (STU:N2U0) FCF Yield % : -14.35 (As of Jun. 22, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Adlai Nortye FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Adlai Nortye's Trailing 12-Month Free Cash Flow is €-17.10 Mil, and Market Cap is €115.87 Mil. Therefore, Adlai Nortye's FCF Yield % for today is -14.35%.

The historical rank and industry rank for Adlai Nortye's FCF Yield % or its related term are showing as below:

STU:N2U0' s FCF Yield % Range Over the Past 10 Years
Min: -16.39 Med: 0 Max: 0
Current: -14.35

STU:N2U0's FCF Yield % is ranked better than
51.61% of 1550 companies
in the Biotechnology industry
Industry Median: -14.395 vs STU:N2U0: -14.35

Adlai Nortye's FCF Margin % for the quarter that ended in Jun. 2023 was 0.00%.

Adlai Nortye FCF Yield % Historical Data

The historical data trend for Adlai Nortye's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adlai Nortye FCF Yield % Chart

Adlai Nortye Annual Data

Trend

Dec21

Dec22

Dec23

FCF Yield %

-18.71

Adlai Nortye Quarterly Data
	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Dec23
FCF Yield %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Adlai Nortye's FCF Yield %

For the Biotechnology subindustry, Adlai Nortye's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adlai Nortye's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adlai Nortye's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Adlai Nortye's FCF Yield % falls into.

Adlai Nortye FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Adlai Nortye's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-52.133	/	278.597265
	=	-18.71%

Adlai Nortye's annualized FCF Yield % for the quarter that ended in Jun. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-7.734	*	4	/	0
	=	N/A%

Adlai Nortye FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Adlai Nortye FCF Yield % Related Terms

Thank you for viewing the detailed overview of Adlai Nortye's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Adlai Nortye (STU:N2U0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (STU:N2U0) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

ANL:USA

Address

685 US Highway 1, North Brunswick, NJ, USA, 08902

Website

https://www.adlainortye.com

Adlai Nortye Ltd is a global clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies for patients across the spectrum of tumor types. The company has robust pipeline of drug candidates it includes buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as four preclinical candidates.

Adlai Nortye (STU:N2U0) Headlines

No Headlines